187 related articles for article (PubMed ID: 36010653)
1. The Landscape of Tumor-Infiltrating Immune Cells in Feline Mammary Carcinoma: Pathological and Clinical Implications.
Nascimento C; Gameiro A; Correia J; Ferreira J; Ferreira F
Cells; 2022 Aug; 11(16):. PubMed ID: 36010653
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
Clin Transl Oncol; 2021 Dec; 23(12):2513-2525. PubMed ID: 34089486
[TBL] [Abstract][Full Text] [Related]
3. Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Simbault L; Abadie J; Loussouarn D; Campone M; Nguyen F
Tumour Biol; 2020 Jan; 42(1):1010428319901052. PubMed ID: 31959092
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model.
Nascimento C; Ferreira F
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188587. PubMed ID: 34237352
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast.
Jamiyan T; Kuroda H; Yamaguchi R; Nakazato Y; Noda S; Onozaki M; Abe A; Hayashi M
Breast Cancer; 2020 Sep; 27(5):880-892. PubMed ID: 32222891
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?
Koletsa T; Kotoula V; Koliou GA; Manousou K; Chrisafi S; Zagouri F; Sotiropoulou M; Pentheroudakis G; Papoudou-Bai A; Christodoulou C; Xepapadakis G; Zografos G; Petraki K; Pazarli E; Koutras A; Kourea HP; Bafaloukos D; Chatzopoulos K; Iliadis A; Markopoulos C; Venizelos V; Arnogiannaki N; Kalogeras KT; Kostopoulos I; Gogas H; Fountzilas G
Cancer Immunol Immunother; 2020 Aug; 69(8):1549-1564. PubMed ID: 32303794
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast.
Kuroda H; Jamiyan T; Yamaguchi R; Kakumoto A; Abe A; Harada O; Masunaga A
BMC Cancer; 2021 Mar; 21(1):286. PubMed ID: 33726701
[TBL] [Abstract][Full Text] [Related]
8. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
[TBL] [Abstract][Full Text] [Related]
9. Histopathological analysis of tumor microenvironment in adrenocortical carcinoma: Possible effects of in situ disorganized glucocorticoid production on tumor immunity.
Ishikawa Y; Yamazaki Y; Tezuka Y; Omata K; Ono Y; Tokodai K; Fujishima F; Kawanabe S; Katabami T; Ikeya A; Yamashita M; Oki Y; Nanjo H; Satoh F; Ito A; Unno M; Kamei T; Sasano H; Suzuki T
J Steroid Biochem Mol Biol; 2024 Apr; 238():106462. PubMed ID: 38232786
[TBL] [Abstract][Full Text] [Related]
10. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
[TBL] [Abstract][Full Text] [Related]
11. Intraepithelial lymphocytes are indicators of better prognosis in surgically resected endometrioid-type endometrial carcinomas at early and advanced stages.
Kono-Sato T; Miyai K; Yamagishi Y; Miyamoto M; Takano M; Matsukuma S; Sato K; Tsuda H
BMC Cancer; 2022 Apr; 22(1):361. PubMed ID: 35366828
[TBL] [Abstract][Full Text] [Related]
12. Correlation between subsets of tumor-infiltrating immune cells and risk stratification in patients with cervical cancer.
Chen R; Gong Y; Zou D; Wang L; Yuan L; Zhou Q
PeerJ; 2019; 7():e7804. PubMed ID: 31616592
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.
Althobiti M; Aleskandarany MA; Joseph C; Toss M; Mongan N; Diez-Rodriguez M; Nolan CC; Ashankyty I; Ellis IO; Green AR; Rakha EA
Histopathology; 2018 Dec; 73(6):887-896. PubMed ID: 29947077
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
15. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
Wang K; Shen T; Siegal GP; Wei S
Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Implication of M2 Macrophages Are Determined by the Proportional Balance of Tumor Associated Macrophages and Tumor Infiltrating Lymphocytes in Microsatellite-Unstable Gastric Carcinoma.
Kim KJ; Wen XY; Yang HK; Kim WH; Kang GH
PLoS One; 2015; 10(12):e0144192. PubMed ID: 26714314
[TBL] [Abstract][Full Text] [Related]
17. TIM-3 Is a Potential Immune Checkpoint Target in Cats with Mammary Carcinoma.
Valente S; Nascimento C; Gameiro A; Ferreira J; Correia J; Ferreira F
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672332
[TBL] [Abstract][Full Text] [Related]
18. Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients.
Ahmadvand S; Faghih Z; Montazer M; Safaei A; Mokhtari M; Jafari P; Talei AR; Tahmasebi S; Ghaderi A
Cell Oncol (Dordr); 2019 Jun; 42(3):343-356. PubMed ID: 30825183
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
[TBL] [Abstract][Full Text] [Related]
20. VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes.
Gameiro A; Nascimento C; Correia J; Ferreira F
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
